ADVERTISEMENT
970x220
.navbar-nav.header-menu { width: 100%; justify-content: center; } .tab-menu-outers .nav-item{ width: unset; } .tab-bar-social.mt-5 { margin-top: 0 !important; } .second-header-menu { margin-top: 27px; padding: 12px 0; border-top: 1px solid #C3C1AE; border-bottom: 1px solid #C3C1AE; } .third-header-menu{ padding: 12px 0; } .bottom-header-menu { margin-right: 25px; text-decoration: none; font-family: "Canicule Display v0.3 Trial" , serif; font-weight: 500; font-size: 15px; line-height: 16px; color: black; } .bottom-header-menu:hover { color: #0A58CA !important; } header .time-date-section { display: flex; align-items: end; } header .mb-header-center .align-items-center .col-3 , header .mb-header-center .align-items-center .col-6, header .top-header-container .col-md-6{ z-index: 100; } header .desktop-menu-bar li:hover a{ background: transparent; color: #2E3192 !important; } @media(max-width: 767px) { header.header.mb-header{ display:none; } .second-header-menu .justify-content-center{ justify-content: start !important; } .second-header-menu ul , .third-header-menu ul{ display: grid; grid-template-columns: 1fr 1fr; width: 100%; } }
Manila Bulletin devider Philippines devider AstraZeneca claims positive Covid medicine trial

AstraZeneca claims positive Covid medicine trial

Published Jun 09, 2022 07:19 am  |  Updated Jun 09, 2022 07:19 am

LONDON, United Kingdom -- A treatment for people at risk of death from coronavirus has revealed good results in a late-stage trial, its maker AstraZeneca announced Wednesday.

AstraZeneca's building in Luton, Britain (Tim Ireland | Xinhua News Agency | Getty Images)

The British pharmaceutical giant, which has already produced a widely used coronavirus vaccine, said the Evusheld jab "provided clinically and statistically significant protection against progression to severe Covid-19 or death".

The phase-three trial was carried out mostly on participants "at high risk of progression to severe Covid-19", AstraZeneca added in a statement.

A total 903 patients worldwide took part in the testing.

"Despite the success of vaccines, many individuals such as older adults, individuals with co-morbidities and those who are immunocompromised, remain at risk for poor outcomes from severe Covid-19," said trial lead Hugh Montgomery, professor of intensive care medicine at University College London.

"Additional options are needed to prevent disease progression and reduce the burden on healthcare systems, especially with the continued emergence of new variants." Evusheld, for the prevention of Covid-19 in people aged 12 and above or those who already have mild coronavirus, consists of two antibodies.

The European Union has approved the jab's eventual widespread use, while it has been granted restricted application in the United States and Britain.

ADVERTISEMENT
300x250
.most-popular .layout-ratio{ padding-bottom: 79.13%; } @media (min-width: 768px) and (max-width: 1024px) { .widget-title { font-size: 15px !important; } }

{{ articles_filter_1561_widget.title }}

{{ item.title }}
.most-popular .layout-ratio{ padding-bottom: 79.13%; } @media (min-width: 768px) and (max-width: 1024px) { .widget-title { font-size: 15px !important; } }

{{ articles_filter_1562_widget.title }}

{{ item.title }}
.most-popular .layout-ratio{ padding-bottom: 79.13%; } @media (min-width: 768px) and (max-width: 1024px) { .widget-title { font-size: 15px !important; } }

{{ articles_filter_1563_widget.title }}

{{ item.title }}

{{ articles_filter_1564_widget.title }}

{{ item.title }}
.mb-article-details { position: relative; } .mb-article-details .article-body-preview, .mb-article-details .article-body-summary{ font-size: 17px; line-height: 30px; font-family: "Libre Caslon Text", serif; color: #000; } .mb-article-details .article-body-preview iframe , .mb-article-details .article-body-summary iframe{ width: 100%; margin: auto; } .read-more-background { background: linear-gradient(180deg, color(display-p3 1.000 1.000 1.000 / 0) 13.75%, color(display-p3 1.000 1.000 1.000 / 0.8) 30.79%, color(display-p3 1.000 1.000 1.000) 72.5%); position: absolute; height: 200px; width: 100%; bottom: 0; display: flex; justify-content: center; align-items: center; padding: 0 72px 0 12px; } .read-more-background a{ color: #000; } .read-more-btn { padding: 17px 45px; font-family: Inter; font-weight: 700; font-size: 18px; line-height: 16px; text-align: center; vertical-align: middle; border: 1px solid black; background-color: white; } .hidden { display: none; }
function showArticleBody(button) { const article = button.closest("article"); const summary = article.querySelector(".article-body-summary"); const body = article.querySelector(".article-body-preview"); const readMoreSection = article.querySelector(".read-more-background"); // Hide summary and read-more section summary.style.display = "none"; readMoreSection.style.display = "none"; // Show the full article body body.classList.remove("hidden"); } document.addEventListener("DOMContentLoaded", () => { let loadCount = 0; // Track how many times articles are loaded const offset = [1, 2, 3, 4, 5, 6, 7, 8, 9, 10]; // The two offset values // changed to 10 from 1 , 2 const currentUrl = window.location.pathname.substring(1); let isLoading = false; // Prevent multiple calls if (!currentUrl) { console.log("Current URL is invalid."); return; } function isNearBottom() { return window.innerHeight + window.scrollY >= document.documentElement.scrollHeight - 100; } function onScroll() { if (isLoading) return; // Skip if already loading if (isNearBottom()) { if (loadCount >= offset.length) { console.log("Maximum load attempts reached."); window.removeEventListener("scroll", onScroll); return; } isLoading = true; // Set flag to prevent multiple calls const currentOffset = offset[loadCount]; window.loadMoreItems().then(() => { loadCount++; // Increment only after successful execution }).catch(error => { console.error("Error loading more items:", error); }).finally(() => { isLoading = false; // Reset flag after execution }); } } window.addEventListener("scroll", onScroll); }); // Mutation Observer for Newly Loaded Articles const observer = new MutationObserver(() => { const articles = document.querySelectorAll(".articles-observe"); if (articles.length > 0) { observeArticles(articles); } }); observer.observe(document.body, { childList: true, subtree: true }); // Intersection Observer for Updating URL function observeArticles(articles) { const intersectionObserver = new IntersectionObserver( (entries) => { entries.forEach((entry) => { if (entry.isIntersecting) { const newUrl = entry.target.getAttribute("data-url"); if (newUrl) { history.pushState(null, null, newUrl); } } }); }, { threshold: 0.1 } ); articles.forEach(article => intersectionObserver.observe(article)); }
.col-md-12.noPadding.col-xs-12:has(.mb-header-bottom) {padding: 0;} .bottom-footer {color: #fff;background-color: #2E3192;padding: 8px 0;} .bottom-footer .bottom-footer-menu {font-family: Inter;font-weight: 400;font-size: 12px;line-height: 16px;padding: 0px 10px !important;color: #fff !important;text-decoration: none; } .bottom-footer .container {display: flex;justify-content: space-between;align-items: center; } .bottom-footer p{font-family: "Inter";font-weight: 400;font-size: 12px;line-height: 16px;margin-bottom: 0;} .subscribe-button{position: absolute;bottom: 15%;right: 11%;} .subscribe-container {position: fixed;display: flex;align-items: center;background-color: white;height: 50px;border-radius: 50px;box-shadow: 1px 3px 8px 3px rgba(0, 0, 0, 0.2);width: 50px;overflow: hidden;transition: width 0.3s ease-in-out;text-decoration: none;white-space: nowrap; } .subscribe-icon {background-color: #2E3192;color: white;border-radius: 50%;width: 50px;height: 50px;display: flex;align-items: center;justify-content: center;font-size: 18px;flex-shrink: 0;transition: border-radius 0.3s ease-in-out; } .subscribe-text {font-size: 18px;font-weight: bold;color: black;margin-left: 0;margin-right: 0;width: 0;visibility: hidden;opacity: 0;transition: opacity 0.3s ease, width 0.3s ease;} .subscribe-container:hover {cursor: pointer;width: 170px;} .subscribe-container:hover .subscribe-icon {border-bottom-right-radius: 0;border-top-right-radius: 0;} .subscribe-container:hover .subscribe-text {visibility: visible;opacity: 1;margin-left: 10px;margin-right: 10px;width: auto;} h6.footer-heading{ font-weight: 700; } #bottom-footer ul li { display: flex; align-items: center; } @media screen and (min-width: 767px) and (max-width: 991px) { .bottom-footer p, .bottom-footer .bottom-footer-menu{ font-size: 9px; } } @media(max-width: 767px) { .bottom-footer .container {display: block;} .bottom-footer .container .justify-content-center{margin-top: 20px !important;} .bottom-footer .container .justify-content-center .list-group{ width: 100%; display: grid; row-gap: 10px; grid-template-columns: 1fr 1fr 1fr; justify-content: unset; } .bottom-footer p{font-size: 10px;} .subscribe-container { width: 50px !important; overflow: hidden;} .subscribe-container:hover { width: 50px !important;} .subscribe-container .subscribe-text {display: none !important;} .subscribe-button{right: 15%;bottom:7%;} } .mb-header-bottom .header-menu:hover { color: #2E3192 !important; } @media(max-width: 400px) { .bottom-footer .container .justify-content-center .list-group{ grid-template-columns: 1fr 1fr; } }
Join Our Newsletters

Sign up by email to receive news.

© 2025 Manila Bulletin The Nation's Leading Newspaper. All Rights Reserved.